1d
Zacks Investment Research on MSNJohnson & Johnson (JNJ) Could Be a Great ChoiceAll investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is ...
Low bond yields and interest rates are often credited with supporting higher prices in the stock market. That's because lower bond yields can make the potentially higher yields offered by stocks ...
NS Partners Ltd reduced its stake in Johnson & Johnson by 3.7%, selling 3,012 shares in Q4. The institutional investor now ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
4d
Zacks Investment Research on MSNJohnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should KnowJohnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), ...
Johnson & Johnson claims a federal judge wrongfully granted its investors class certification for losses related to purported ...
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BridgeBio Pharma (BBIO – Research Report), ...
Guggenheim reiterated their neutral rating on shares of Johnson & Johnson (NYSE:JNJ – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. JNJ has been the topic of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results